Dr. Philip Boehme new CEO of HAL Allergy
After earning degrees from KIT Karlsruhe, Witten/Herdecke University, and spending time at the University of Washington, Dr. Boehme began his clinical career in pulmonology, treating allergy and asthma patients while conducting research.
Before joining HAL Allergy as CEO, Dr. Boehme scaled Evotec SE’s Just-Biologics business into a fast-growing biopharmaceutical producer. He previously worked at McKinsey & Company, focusing on pharma R&D and commercial strategy, and at Bayer on clinical and non-clinical cardiovascular and lung projects. He also holds an MBA from the University of Illinois.
HAL Allergy is dedicated to the development, production and distribution of allergen immunotherapies (AIT) for the treatment and prevention of allergic diseases. With a strong allergen immunotherapy portfolio and a focus on multiple therapeutic areas, HAL Allergy develops products following its mission to improve the quality of lives of patients by providing biopharmaceutical products for causal treatment.
Dr. Ernest-W. Droege, CEO of Droege Group and shareholder of HAL Allergy, states: “First and foremost, we want to thank Alex Huybens for his commitment to HAL Allergy over the past decades. He and his team have developed HAL Allergy into a leading player in AIT, demonstrating outstanding leadership and executive skills. With Dr. Philip Boehme joining as our new CEO, we are executing our succession plans and taking the next step to build upon the solid foundation that Alex and his team have established.“ Alex Huybens will remain Advisor to the Supervisory Board of HAL Allergy.
Dr. Werner Lanthaler, Chair of the Supervisory Board of HAL Allergy, states: “Philip joins HAL Allergy at a moment full of new scientific and commercial opportunities. His strong track record of building high-performing teams and a deep understanding of patients are the ideal combination for our ambitions. Under his leadership, we will strengthen our portfolio, accelerate growth, and expand beyond our current activities to increase our impact on patients and their quality of lives.”
Dr. Philip Boehme on his new role: “I am proud to join HAL Allergy and drive growth with an energized team, expanding our impact on the quality of patient’s lives and serving our professional customers. Allergies affect us all — tackling them means pushing beyond today’s limits. I'm committed to making a lasting impact, overcoming allergies one by one.”
Contact Information
HAL Allergy B.V.
Monique Lutgens – Manager Corporate Communications
Tel. + 31 (0)88 1959010
Email: corporatecommunications@hal-allergy.com
